Un Audited Financial Result for 30th September, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bacil Pharma's Q2 FY26 results show the company had zero revenue from operations, with total revenue of just ₹5.49 lakhs (entirely from 'other income'), down sharply from ₹100.25 lakhs in Q1 FY26. Profit after tax collapsed to ₹1.38 lakhs versus ₹66.87 lakhs in the previous quarter. The statutory auditor flagged multiple serious concerns in an Emphasis of Matter, including: inability to verify the end-use of funds raised through preferential allotment, inability to confirm related party transactions, non-compliance with GST and TDS filing/deposit requirements, and reliance solely on management representations for investments and deposits. The auditor also invoked a 'Basis for Disclaimer of Opinion,' stating they could not obtain sufficient evidence. Operating cash flow turned sharply negative at ₹(142.62) lakhs versus ₹40.08 lakhs last year, and the cash balance fell from ₹285.73 lakhs to ₹159.38 lakhs.
This is a deeply concerning filing — the company has no operating business revenue, the auditor has flagged significant compliance, documentation, and disclosure failures, and cash is being burned at a worrying rate. Shareholders should treat this as a high-risk situation warranting close scrutiny of management's use of funds and the company's ability to continue as a going concern.